Dr Viviana Ossa, MD | |
Cond Parkville Plaza Apt 603, Guaynabo, PR 00969 | |
(787) 672-1666 | |
(787) 292-0130 |
Full Name | Dr Viviana Ossa |
---|---|
Gender | Male |
Speciality | Allergy & Immunology - Allergy |
Location | Cond Parkville Plaza Apt 603, Guaynabo, Puerto Rico |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1669444949 | NPI | - | NPPES |
15865 | Other | PR | LIC |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207KA0200X | Allergy & Immunology - Allergy | 15865 (Puerto Rico) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Viviana Ossa, MD Cond Parkville Plaza Apt 603, Guaynabo, PR 00969 Ph: (787) 672-1666 | Dr Viviana Ossa, MD Cond Parkville Plaza Apt 603, Guaynabo, PR 00969 Ph: (787) 672-1666 |
News Archive
ProPublica profiles Anne Johnson, a 41-year-old single mother in California "whose family has been uninsured since she lost her job as a secretary in February," and explores how health reform could affect her. Johnson "needs her aortic valve replaced, but without insurance she can't afford the surgery. She is supposed to get checkups every six months, but that is also too expensive - so she has put them off."
Teva Pharmaceutical Industries Ltd. announced today the U.S. District Court for the Southern District of New York has found in favor of Teva in the Company's patent infringement lawsuit against Momenta Pharmaceuticals, Inc./Sandoz Inc. and Mylan Laboratories Inc./Natco Pharmaceuticals regarding Teva's relapsing-remitting multiple sclerosis (RRMS) product, COPAXONE.
The second American Association for Cancer Research Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic provides attendees with an overview of the most advanced cancer research in a variety of fields, including the tumor microenvironment, microRNAs, signal transduction and novel therapeutic development.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused over 9.263 million cases and taken more than 477,000 lives as of June 24, 2020 – just six months after the initial outbreak in Wuhan, China, was reported. The illness, called COVID-19 disease, caused by SARS-CoV-2 is a severe pneumonic illness, caused by the entry of the virus into the type II alveolar cells.
A new study finds that states don't always flex their muscle when it comes to regulating insurance rates. Meanwhile, there is movement at the top for WellPoint.
› Verified 3 days ago